Iclusig 15mg 30s Tablets

$2,883.21

Tablets per bottle: 30, Manufacturer:

Description

Composition Ponatinib 15mg
Substitutes Ponatinib 15mg
Shipping class Room Temperature

Medicine Overview of Iclusig 15mg 30s

uses

Uses of Iclusig 15mg 30s

Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
uses

Iclusig 15mg 30s side effects

Common

hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation,
arthralgia, nausea, and pyrexia, Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.
uses

How to use Iclusig 15mg 30s

Take ICLUSIG exactly as your healthcare provider tells you to take it. Swallow ICLUSIG tablets whole. Do not crush or dissolve ICLUSIG tablets. You may take ICLUSIG with or without food.

How Iclusig 15mg 30s works

Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or T315I mutant BCR-ABL when compared to controls.

In Depth Information on Iclusig 15mg 30s

Expert advice for Iclusig 15mg 30s

  • Congestive Heart Failure: Monitor patients for signs or symptoms of congestive heart failure and treat as clinically indicated.
  • Hypertension: Monitor for high blood pressure and treat as clinically indicated.
  • Pancreatitis: Monitor serum lipase monthly; interrupt or discontinue Iclusig.
  • Hemorrhage: Interrupt Iclusig for serious or severe hemorrhage.
  • Fluid Retention: Monitor patients for fluid retention; interrupt, reduce, or discontinue Iclusig.
  • Cardiac Arrhythmias: Monitor for symptoms of arrhythmias.
  • Myelosuppression: Thrombocytopenia, neutropenia, and anemia may require dose interruption or reduction. Monitor complete blood counts every 2 weeks for 3 months and then monthly and as clinically indicated. Interrupt Iclusig for ANC < 1000/mm3 or thrombocytopenia < 50,000/ mm3.
  • Tumor Lysis Syndrome: Ensure adequate hydration and correct high uric
    acid levels prior to initiating therapy with Iclusig.
  • Compromised Wound Healing and Gastrointestinal Perforation: Temporarily interrupt therapy in patients undergoing major surgical procedures.

Iclusig 15mg 30s related warnings

Special precautions for Iclusig 15mg 30s

alcohol
Alcohol
There is no adequate data.Please contact your doctor.
pregnancy
Pregnancy
WEIGH RISKS VS BENEFITS
Based on its mechanism of action and findings in animals, Iclusig can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies with Iclusig in pregnant women. Advise women to avoid becoming pregnant while taking Iclusig. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
lactation
Lactation
WEIGH RISKS VS BENEFITS
It is unknown whether ponatinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ponatinib, a decision should be made whether to discontinue nursing or to discontinue Iclusig, taking into account the importance of the drug to the mother.
driving
Driving
There is no adequate data.Please contact your doctor.
kidney
Kidney
caution
Iclusig has not been studied in patients with renal impairment. Although renal excretion is not a major route of ponatinib elimination, the potential for moderate or severe renal impairment to affect hepatic elimination has not been determined.
liver
Liver
caution
ICLUSIG can cause liver problems, including liver failure, which can be severe and may lead to death. Your healthcare provider will do blood tests before and during your treatment with ICLUSIG to check for liver problems.

What if you miss a dose of Iclusig 15mg 30s?

If you miss a dose of ICLUSIG, take your next dose at your regular time. Do not take 2 doses at the same time to make up for a missed dose.

Additional information

Weight 0.045 kg